![conference banner](/images/conference-banner.jpeg)
Abstract
Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb / IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb / IIIa blockade when given in conjunction with heparin, chronic oral GPIIb / IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
Keywords: antiplatelet therapies, cerebrovascular diseases, atherosclerosis, intravascular thrombus, clopidogrel, platelet gpIIb/IIIa antagonists, thromboembolic disorders, thrombotic disorders
Current Pharmaceutical Design
Title: Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Volume: 9 Issue: 28
Author(s): Shaker A. Mousa
Affiliation:
Keywords: antiplatelet therapies, cerebrovascular diseases, atherosclerosis, intravascular thrombus, clopidogrel, platelet gpIIb/IIIa antagonists, thromboembolic disorders, thrombotic disorders
Abstract: Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb / IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb / IIIa blockade when given in conjunction with heparin, chronic oral GPIIb / IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
Export Options
About this article
Cite this article as:
Mousa A. Shaker, Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond, Current Pharmaceutical Design 2003; 9 (28) . https://dx.doi.org/10.2174/1381612033453893
DOI https://dx.doi.org/10.2174/1381612033453893 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Anti-Oxidant Drugs: Novelties and Clinical Implications in Cerebellar Ataxias
Current Neuropharmacology Gene Therapy as a Novel Pharmaceutical Intervention for Stroke
Current Pharmaceutical Design Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design A2A Adenosine Receptor Agonists and their Potential Therapeutic Applications. An Update
Current Medicinal Chemistry Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Anti-inflammatory and Antioxidant Agents from Salvia Genus (Lamiaceae): An Assessment of the Current State of Knowledge
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures
Current Vascular Pharmacology Challenges and Promises of Developing Thrombin Receptor Antagonists
Recent Patents on Cardiovascular Drug Discovery Accelerated Delimitation of the Infarct Zone by Capillary-Derived Nestin- Positive Cells in Aged Rats
Current Neurovascular Research Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome
Current Neurovascular Research Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews Oral Antiplatelet Therapy for Acute Coronary Syndromes: Aspirin, P2Y12 Inhibition and Thrombin Receptor Antagonists
Current Drug Targets Growing Collateral Arteries On Demand
Recent Patents on Cardiovascular Drug Discovery A Novel Assay Platform for the Detection of Translation Modulators of Spermidine/ Spermine Acetyltransferase
Current Pharmaceutical Design Erratum
Current Medicinal Chemistry Receptor Proteins for Nongenomic Actions of Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Changes in Cognition, Depression and Quality of Life after Carotid Stenosis Treatment
Current Neurovascular Research Role of AMPK in Diabetic Cardiovascular Complications: An Overview
Cardiovascular & Hematological Disorders-Drug Targets Role of Chymase in Preeclampsia
Current Vascular Pharmacology